Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23BrFNO2 |
| Molecular Weight | 420.315 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C3=CC=C(Br)C=C3
InChI
InChIKey=RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
Bromperidol decanoate is a long-acting antipsychotic medication used in at least Belgium, Germany, Italy, and the Netherlands. In clinical trials, Bromperidol decanoate was effective in the treatment of residual schizophrenia, with significant differences between before and after treatment ratings for symptoms. The preparation seems to be less potent than other depot antipsychotics (such as fluphenazine and haloperidol decanoate) and better than placebo injection. If bromperidol decanoate is available to the clinician it may be a viable choice, especially when there are reasons not to use fluphenazine or haloperidol decanoate.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Clinical experiences in an open and a double-blind trial. | 1978 Jan-Feb |
|
| Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. | 1978 Jan-Feb |
|
| Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range. | 1978 Mar |
|
| Clinical evaluation of bromperidol versus haloperidol in psychotic patients. | 1980 |
|
| Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. | 1992 Nov |
|
| Possible interaction between cisapride and bromperidol. | 1997 Jan |
|
| [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol]. | 1998 Feb |
|
| Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. | 2001 Apr 8 |
|
| The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. | 2001 Aug |
|
| Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay. | 2003 Dec |
|
| Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. | 2004 Nov 26 |
|
| Pharmacokinetic parameters of bromperidol in Korean subjects. | 2006 Aug |
|
| Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. | 2006 Mar |
|
| Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia. | 2007 Apr |
|
| Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. | 2007 Dec |
|
| Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | 2007 Jun |
|
| The effects of atypical and conventional antipsychotics on reduced processing speed and psychomotor slowing in schizophrenia: a cross-sectional exploratory study. | 2008 Apr |
|
| The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). | 2008 Dec 22 |
|
| Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. | 2009 Dec |
|
| Automated on-line in-tube solid-phase microextraction coupled with HPLC/MS/MS for the determination of butyrophenone derivatives in human plasma. | 2009 Jun |
|
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
| Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. | 2010 Aug |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Improvement of mutism in a catatonic schizophrenia case by add-on treatment with amantadine. | 2010 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=bromperidol
Oral Schizophrenia:
Adult: 1-15 mg daily, up to 50 mg daily.
Intramuscular Schizophrenia:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Intramuscular Psychoses:
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Oral Psychoses:
Adult: 1-15 mg daily, up to 50 mg daily.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
||
|
WHO-VATC |
QN05AD06
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
||
|
WHO-ATC |
N05AD06
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB05923MIG
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
3737
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
407
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
100000091973
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
DTXSID0022690
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
C76439
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
DB12401
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
LYH6F7I22E
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
m2722
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
C006820
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
BROMPERIDOL
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
759275
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
233-943-3
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
19777
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
10457-90-6
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL28218
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY | |||
|
2448
Created by
admin on Fri Dec 15 15:00:21 GMT 2023 , Edited by admin on Fri Dec 15 15:00:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
